# Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.

> **NCT07679412** · NA · RECRUITING · sponsor: **LucasBio** · enrollment: 5 (estimated)

## Conditions studied

- CMV Retinitis

## Interventions

- **BIOLOGICAL:** LB-DTK-CMV

## Key facts

- **NCT ID:** NCT07679412
- **Lead sponsor:** LucasBio
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-27
- **Primary completion:** 2027-08-14
- **Final completion:** 2027-08-14
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07679412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07679412, "Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07679412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*